Starting a Swedish national quality registry for orthognathic surgery: a tool for auditing fundamentals of care.

BACKGROUND: National quality registries (NQRs) provide open data for user-directed acquisition. National Quality Registry (NQR) data are often used to analyze the rates of treatment success and adverse events for studies that aim to improve treatment quality and patient satisfaction. Thus, NQRs promote the goal of achieving evidence-based therapies. However, the scientific literature seldom focuses on the complex process of initiating, designing, and implementing an NQR. Starting an NQR may be particularly challenging in a setting where specialized care is decentralized, such as orthognathic surgery in Sweden. The present study describes the initiation and early phases of a new NQR for orthognathic surgery in Sweden. METHODS: The initial inventory phase included gaining knowledge on regulations, creating economic plans, and identifying pitfalls in existing NQRs. Next, a crude framework for the registry was achieved. Outcome measures were selected with a nation-wide questionnaire, followed by a Delphi-like process for selecting parameters to include in the NQR. Our inclusive process comprised a stepwise introduction, feedback-based modifications, and preparatory educational efforts. Descriptive data were collected, based on the first 2 years (2018-2019) of registry operation. RESULTS: Two years after implementation, 862 patients that underwent 1320 procedures were registered. This number corresponded to a 91% coverage rate. Bimaxillary treatments predominated, and the most common were a Le Fort I osteotomy combined with a bilateral sagittal split osteotomy (n = 275). Reoperations were conducted in 32 patients (3.6%), and the rate of patient satisfaction was 95%. CONCLUSIONS: A National Quality Registry should preferentially be started and maintained by an appointed task force of active clinicians. A collaborative, transparent, inclusive process may be an important factor for achieving credibility and high coverage, particularly in a decentralized setting.

Surgical treatment of recurring ameloblastoma, are there options?

Our aim was to evaluate the treatment given to patients with intraosseus ameloblastomas with special emphasis on recurrence and the outcomes of primary and secondary resection. Forty-eight patients who were treated for intraosseous ameloblastoma at 8 centres across Sweden met the inclusion criteria. They showed typical distribution of age, sex, site of lesion, and characteristic presenting features. Eleven of the 48 were initially treated with radical resection and none recurred. Twenty-two of the remaining 37 who were initially treated by conservative resection presented with recurrences. Sixteen of the 22 then had conservative secondary resections, which resulted in further recurrence in 6 patients. Initial radical resection is therefore superior to conservative management as far as recurrences are concerned. We argue, however, that a conservative surgical approach is adequate for many intraosseous ameloblastomas with limited extension, because relapse can be followed by radical resection if clinically indicated in selected cases.

Basic fibroblast growth factor (bFGF) in saliva and oral mucosa in patients with oral lichen planus: preliminary observations.

OBJECTIVE: Basic fibroblast growth factor (bFGF) is important for wound healing and tissue repair. This study measures the concentration of bFGF in oral lichen planus (OLP) affected mucosa and in the saliva of patients with OLP. STUDY DESIGN: Samples of saliva, OLP-affected mucosa, and clinically healthy mucosa were obtained from 11 patients. Control samples were obtained from healthy volunteers. The bFGF content of tissue samples and saliva was examined by ELISA. RESULTS: The mean bFGF concentration in saliva from OLP patients was 5.9 pg/mL, SD 2.9, compared with 0.3 pg/mL, SD 0.3, in the control group, (P>.01). The bFGF content in the OLP tissue was 90.6 microg/mg protein, SD 39.5, in clinically normal mucosa from OLP individuals it was 46.2 microg/mg protein, SD 12.0 (P=.02), and in the control group 46.2 microg/mg protein, SD 11.5 (P>.01). CONCLUSION: OLP-affected mucosa contained significant more bFGF than nonaffected mucosa in OLP and healthy mucosa in control group. There is no difference between nonaffected mucosa in OLP and control group. Saliva in OLP patients contained more bFGF than saliva in control patients.

Basic fibroblast growth factor in human saliva decreases with aging.

OBJECTIVE: Basic fibroblast growth factor (bFGF) has significant properties in wound healing and tissue repair and is suggested to be of importance for the maintenance of mucosal integrity in the upper digestive tract. The purpose of the present study was to identify any age-dependent variations in the concentration of bFGF in human saliva. STUDY DESIGN: Nonprospective, cross-sectional pilot study. METHODS: The study was based on findings from 182 healthy volunteers with ages ranging from 4 to 97 years. Mixed saliva samples were obtained by drooling. The saliva concentration of bFGF was determined with a commercially available enzyme-linked immunosorbent assay kit. RESULTS: The mean saliva concentration of bFGF was 0.41 pg/mL with no gender differences. In persons aged 4 to 19 years, the mean concentration was 0.72 pg/mL; in those aged 20 to 65 years, 0.33 pg/mL; and in those aged 66 to 97 years, 0.005 pg/mL. These age-dependent differences were highly significant. In the youngest group the saliva concentration of bFGF varied more than in the other groups. CONCLUSIONS: The saliva concentration of bFGF varies with individual age, with the highest levels among young individuals, even levels during a mature phase of life, and low levels toward the end of the life cycle. This strongly suggests a physiological implication of bFGF in saliva.